Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-Host Disease without Delaying Immune Reconstitution

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 11, 2012, Pages 1656-1663

  Law, Jason ^a   Cowan, Morton J ^b   Dvorak, Christopher C ^b   Musick, Lisa ^c   Long Boyle, Janel R ^c   Baxter Lowe, Lee Ann ^d   Horn, Biljana ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alemtuzumab; Hematopoietic cell transplant; Malignant; Nonmalignant; Pediatric; Reduced toxicity regimen

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE COURSE; ENGRAFTMENT; EVENT FREE SURVIVAL; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HLA SYSTEM; HUMAN; IMMUNE DYSREGULATION; INBORN ERROR OF METABOLISM; INFANT; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PROMYELOCYTIC LEUKEMIA; RELAPSE; SCHOOL CHILD; T LYMPHOCYTE; VIRUS INFECTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; B-LYMPHOCYTES; BUSULFAN; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; MYELOABLATIVE AGONISTS; NEUTROPHILS; PROSPECTIVE STUDIES; RECURRENCE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; YOUNG ADULT;

EID: 84867528070     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.05.006     Document Type: Article

References (20)

1. Wayne A.S., Baird K., Egeler R.M. Hematopoietic stem cell transplantation for leukemia. Pediatr Clin North Am 2010, 57:1-25.
2. Smiers F.J., Krishnamurti L., Lucarelli G. Hematopoietic stem cell transplantation for hemoglobinopathies: current practice and emerging trends. Pediatr Clin North Am 2010, 57:181-205.
3. Boelens J.J., Prasad V.K., Tolar J., Wynn R.F., Peters C. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am 2010, 57:123-145.
4. Myers K.C., Davies S.M. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant 2009, 15:279-292.
5. Horn B., Baxter-Lowe L.A., Englert L., et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 2006, 37:263-269.
6. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 1988, 332:323-327.
7. Stauch D., Dernier A., Sarmiento Marchese E., et al. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity. PLoS One 2009, 4:e4709.
8. Morris E.C., Rebello P., Thomson K.J., et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003, 102:404-406.
9. Ho A.Y., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004, 104:1616-1623.
10. Styczynski J., Tallamy B., Waxman I., et al. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 2011, 46:790-799.
11. Przepiorka D., Weisdorf D., Martin P., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
12. Bearman S.I., Anderson G.L., Mori M., Hinds M.S., Shulman H.M., McDonald G.B. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993, 11:1729-1736.
13. Horn B., Soni S., Khan S., et al. Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies. Bone Marrow Transplant 2009, 43:469-476.
14. Marsh R.A., Vaughn G., Kim M.O., et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 2010, 116:5824-5831.
15. Ozyurek E., Cowan M.J., Koerper M.A., Baxter-Lowe L.A., Dvorak C.C., Horn B.N. Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders. Bone Marrow Transplant 2008, 42:83-91.
16. van Besien K., Dew A., Lin S., et al. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma 2009, 50:1809-1817.
17. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002, 99:4357-4363.
18. Vassiliou G.S., Webb D.K., Pamphilon D., Knapper S., Veys P.A. Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath. Br J Haematol 2001, 114:701-705.
19. Ratzinger G., Reagan J.L., Heller G., Busam K.J., Young J.W. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003, 101:1422-1429.
20. Osterborg A., Dyer M.J., Bunjes D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997, 15:1567-1574.